加味二仙汤联合钙尔奇D对绝经后骨质疏松患者骨密度、骨代谢标志物、视觉模拟评分(VAS)的影响研究

Effect of Jiawei Erxian Decoction Combined with Caltrate D on Bone Mineral Density,Bone Metabolism Markers and Visual Analogue Scale( VAS) in Postmenopausal Osteoporosis Patients

探讨加味二仙汤、钙尔奇D联合治疗绝经后骨质疏松症患者对其骨密度、骨代谢标志物、视觉模拟评分法(VAS)得分影响效果。选取该院于2018年7月至2019年5月期间收治的87例绝经后骨质疏松症患者作为本次研究对象并予以随机分组(随机数字表法)。对照组(n=43)在常规治疗基础上加用钙尔奇D,研究组(n=44)在对照组基础上加用加味二仙汤,记录两组治疗前后骨密度、骨代谢标志物、VAS法得分情况。在采取不同方案治疗之前,两组患者在骨密度检测值、骨代谢标志物检测值、VAS法得分均无显著差异(P>0.05)。治疗后,两组患者的腰椎L1-4、股骨颈、髋部大粗隆等处骨密度检测值较之前有效提高,且研究组治疗后的各项骨密度测量值均显著高于对照组(P<0.05);两组患者的OCN、BALP、TRACP-5b、CTX、PTH等骨代谢标志物检测值较之前明显降低,且研究组患者治疗后的各项骨代谢标志物水平均显著低于对照组(P<0.05);研究组患者的VAS评分情况下降幅度明显优于对照组(P<0.05)。加味二仙汤、钙尔奇D联合治疗绝经后骨质疏松症效果显著,具有较好的临床应用价值。

To investigate the effect of modified Erxian Decoction and Caltrate D on bone mineral density,bone metabolism markers and visual analogue scale( VAS) scores in postmenopausal osteoporosis patients,87 cases of postmenopausal osteoporosis patients in the author’ s hospital from July 2018 to May 2019 were selected as the research objects and randomly divided into two groups( random number table method). The control group( n= 43) was treated with Caltrate D based on conventional treatment,and in the study group( n = 44) Jiawei Erxian Decoction was added on the basis of the control group. Bone mineral density,bone metabolic markers and VAS scores of the two groups before and after treatment were recorded. Before adopting different treatment regimens,there was no significant difference between the two groups of patients in the detection values of bone mineral density,bone metabolism markers,and VAS scores( P>0. 05). After treatment,the bone mineral density of the lumbar spine L1-4,femoral neck,and greater trochanter of the hip were effectively improved in the two groups of patients compared with before,and the bone mineral density measurements of the study group after treatment were significantly higher than those of the control group( P < 0. 05). The detection values of bone metabolism markers such as OCN,BALP,TRACP-5 b,CTX,and PTH in the two groups of patients were significantly lower than before,and the levels of bone metabolism markers in the study group after treatment were significantly lower than those in the control group( P<0. 05). The decrease in VAS score of the study group was significantly better than that of the control group( P<0. 05).The combined treatment of Jiawei Erxian Decoction and Caerqi D for postmenopausal osteoporosis was more effective and had clinical application value.